Nanexa will participate in DDF Summit 2026 in Berlin, Germany on 18-20 May

Dr. Joel Hellrup serves as Head of Pharmaceutical R&D at Nanexa and will give a talk on 19 May about PharmaShell®: Atomic layer deposition enabling once‑monthly and once‑quarterly semaglutide depots, with clinical proof‑of‑concept from liraglutide.